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We have previously defined a  set  of antigenic determinants shared by human T 
cells  and  the  surface  Ig-bearing cells  from a  large  number of patients  with  B  cell 
chronic lymphocytic leukemia  (B-CLL)  (I,  2).  These  antigenic  determinants  were 
recognized by rabbit antisera raised against human T  cells.  Absorption experiments 
showed that T  cells from human peripheral blood (PBL), from the thymus, and from 
T  cell chronic lymphocytic leukemia (T-CLL) displayed all these antigenic determi- 
nants; cells from patients with B-CLL may express all, none, or an incomplete set of 
these determinants. Finally, these antigens are confined to the E-rosetting population 
of PBL and are not expressed on B cell lymphoid cell lines (B-LCL) in culture, B cell 
Burkitt-like lymphomas, and plasmocytomas. Absorptions also revealed that investi- 
gations of the exact distribution pattern of these antigens on T  cells were not possible 
using these rabbit  antisera,  because they primarily contained antibodies specific for 
human  T  cells.  These  investigations  are  reported  here  for one  of these  antigenic 
determinants shared by human T cell and B-CLL cells that is defined by a monoclonal 
antibody. 
Materials and Methods 
Preparation of the Monoclonal Antibody.  Biozzi's high responder strain of mice were immunized 
by one intravenous injection of 50 ×  10  n T-CLL cells as briefly described elsewhere (3, 4). After 
4 d, mice were sacrificed, and  108 spleen cells were mixed with  the nonsecretor  myeioma cell 
line NS1 (5) at a ratio 10:1 and pelleted by centrifugation.  The cells were resuspended  in 1 mi 
polyethylene  glycol (PEG  6000 [Sigma  Chemical  Co.,  St.  Louis,  Mo.]  33%  in  RPMI-1640 
[Grand Island Biological Co., Grand Island, N. Y.] Hepes). After 3 rain at room temperature, 
the  mixture  was centrifuged  for another 3 min.  PEG was then  removed,  and the cells were 
gently resuspended  in 4 ml fetal calf serum  (FCS) for l0 min. The cells were then diluted  by 
adding 20 ml of RPMI-1640, containing pyruvate, L-glutamine, and antibiotics,  and plated in 
0.1-ml portions into a 96-well microcuhure plate (Falcon 3040; Falcon Labware, Div. of Becton, 
Dickinson & Co., Oxnard, Calif.). Progressive selection was carried out for 2 wk with hypoxan- 
thine-aminopterin-thymidine  (HAT) medium.  HAT 0.1 ml was added after 24 h, and half the 
medium (0.1 ml) was replaced with fresh HAT medium on days 2, 3, 6, 9, and 13. Hypoxanthine, 
thymidine  medium was then added every 2-3 d for another 2 wk. The cell cultures were then 
maintained  in RPMI-1640,  containing 15% FCS with pyruvate, L-glutamine, and antibiotics. 
Clones of living hybrids were observed by day 7 or 8 under the microscope, and the supernates 
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of hybrids were screened repeatedly for antibody production from the 3rd wk onward. Whenever 
a positive well was detected, the culture was expanded in a 24-well Costar plate (Costar 3524; 
Costar Data Packaging, Cambridge, Mass.), and the hybrid was cloned, while the screening 
was repeated. Cloning of the cells, achieved by serial dilution of cell suspensions, was performed 
twice on relevant hybrid. The cloned hybrid cells were then injected intraperitoneally into nude 
mice resulting in tumors that were serially transplanted.  Ascites fluid from the tumor-bearing 
nude mice were individually checked for antibody activity. 
Antibody Assays.  Antibodies  to  the  immunizing  T  cells were  detected  in  a  complement- 
dependent microcytotoxicity test as described in (6). A panel of normal T  and B cells,  thymus 
cells, B cell lines, and cells from patients with various B and T  cell malignancies was also used 
for the screening. Cells were used fresh or after freezing, with identical results. 
Rabbit Antisera.  The preparation and specificity of these antibodies has been described  in 
detail elsewhere (2, 7). 
Characterization of the Monoclonal Antibody.  Immunoglobulins from the ascites fluid of tumor- 
bearing nude mice were concentrated by ammonium sulfate precipitation (35% saturation) and 
examined  by  immunodiffusion  with  antisera  prepared  in  rabbits  against  purified  murine 
myeloma proteins. These antisera  and  the reference myeloma proteins were purchased  from 
(Bionetics Laboratory Products, Litton Bionetics Inc., Kensington, Md.). The protein concen- 
tration was determined by the Lowry method (8). 
Results 
Obtention  of a  Monoclonal Antibody  Recognizing an Antigen  Shared by Human  T  Cells and 
B-CLL  Cells.  We isolated  hybrids  that  produced  antibodies  to E + PBL and  not  E- 
PBL.  A  few of these antibodies  also recognized  cells from patients  with  B-CLL.  We 
were able to clone an hybrid of this type twice and named it A50.  In nude mice, A50 
gave rise  to  a  transplantable  tumor  and  ascites  fluid,  containing  antibody  in  high 
tiler  (reacting  at  10-4-10 -3  dilution  with  human  E +  PBL  in  a  complement  [C]- 
dependent  eytotoxic  test).  The  immunoglobulin  produced  by  A50  is  an  IgGza  K 
chain, as revealed by immunodiffusion  assays (results not shown). 
A50 recognized the E + PBL from every normal donor tested.  On a  panel of 39 B- 
CLL, A50 recognized cells from 17 patients. Table I compares the cytotoxicity of A50 
on this panel of B-CLL with that  of four rabbit  antisera obtained  by immunization 
with  various T  cells and  absorption  on  B-LCL.  By absorption  experiments,  we had 
previously shown that these antisera recognized human T  cell-specific antigens and a 
set of antigens  shared  by T  cells and  B-CLL cells,  but  lacking on  B  cell  peripheral 
TABLE  I 
Comparison of the Cytotoxic Patterns of a Monoclonal Antibody and Four Rabbit Anti-T Cell Antisera on 
B-CLL 
B-CLL tested  A50 
Rabbit antisera raised against 
T  cell lym-  Sgzary  Thymus  XLA PBL*  phoma 
3, 33, 39, 41, 42, 43, 44, 50, 62,  +:~  +  +  +  + 
63, 66, 67, 68, 69 
18, 32, 70  +  +  -  +  + 
L  -§  -  +  -  - 
2,4,5,6, 7,  10, 13, 19,23,25,  -  .... 
34, 49,  u 52,  54, 59, 60, 61, 
65, 72, 73, 76 
* PBL obtained from a patient with X-linked agammaglobulinemia (Bruton's type) (XLA). 
:~ A B-CLL was considered positive if =:"70% of the cells were lysed by the antiserum. 
§ A B-CLL was considered negative if ~20% of the cells were lysed by the antiserum. 
II B-CLL 49 had 40% E + cells, and 35-45% of the cells were recognized by the antisera: it was therefore considered negative. BOUMSELL  ET  AL.  BRIEF  DEFINITIVE  REPORT  231 
blood lymphocytes (B-PBL)  (1, 2). With the exception of an antiserum raised against 
thymus  cells, A50  recognized  the  same  B-CLL  cells  as  the  antisera  raised  against 
S6zary  cells, T  cell  peripheral  blood  lymphocytes  (T-PBL),  and  T  cell  lymphoma 
cells (Table I). 
Distribution  of the  Antigen Shared  by  Human  T  Cells  and  B-CLL  Cells  on  Normal 
Lymphocytes.  Table II shows the populations of normal lymphoeytes recognized  by 
A50. Cells forming sheep erythroeyte rosettes (E +) from various organs are recognized 
by A50.  However, in the thymus,  only a  proportion of cells --  (varying  from 33 to 
59%) -- is recognized. This proportion of cells does not seem to vary with the age of 
the donor, and cells carrying this antigen could readily be detected in the thymus of 
a 14-wk-old fetus. We could not find, in any fraction containing B cells and monocytes, 
any cell recognized by A50. Nor did we find any other positive non-T cell malignancy: 
we have now investigated the cells from 14 patients with common acute lymphoblastic 
leukemia (ALL),  1 patient with pre-B cell ALL,  11 patients with B cell lymphoma,  1 
patient with plasmocytoma, 4 patients with acute myeloblastic leukemia, and the cells 
from 3 B-LCL. 
T Cell Malignancies Displaying the Antigen Shared by Human T Cells and B-CLL CeUs.  As 
A50 did not recognize all thymocytes, and presumably these were the immature ones, 
we have investigated  various T  cell malignancies.  We have previously shown, using 
rabbit antisera, that T cell malignancies can be subdivided on the basis of the surface 
TABLE II 
Distribution oft& Antigen Shared by Human T Cell and B-CLL Cells on Normal Lymphoid Cells 
Number of in- 
Origin of the cells  dividuals 
Antisera 
A50  a-Thymus*  a-B-CLL* 
Thymuses  7 
Fetal  14 wk old  59".~  95  ag5 
16 or 17 wk old  33  51  12 
22 wk old  63  95  8 
28 wk old  45  95  9 
Child  8  mo old  39  95  ag5 
4 yr old  37  94  ~5 
Unknown  51  95  ag5 
Lymph nodes 
E-§  1  ag5  ag5  95 
E+§  89  89  ag5 
E-  1  26  27  74 
E +  93  90  11 
Spleen 
E-  1  ~5  ag5  75 
E +  88  88  ~5 
E-  1  ag5  ~5  60 
E "~  79  85  ag5 
Tonsils 
E-  1  ag5  ag5  95 
E +  46  65  ~5 
PBL 
E-  16  ~5-20][  ag5-20  60-90 
E +  70-90~[  70-90  ag5-10 
* Preparation  of the antisera against thymus cells and against B-CLL cells has been described elsewhere (2,  7). 
Values represent  the cytotoxic index calculated as follows:  percent  dead in experimental -  percent  dead in (~ control/ 
100  -  percent  dead in C control ×  100. 
§ Cells were separated over a  Ficoll  gradient after rosetting with 2-aminoethylisothiouronium bromide hydrobromide- 
treated sheep erythrocytes as previously described  (2), into E + and E- cells. 
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T  cell antigens they display (7, 9). Table III shows that A50 did not recognize all T 
cell malignancies;  all T-CLL cells and S6zary cells we tested were recognized but no 
T  cell-ALL cells and only the cells from some T  lymphomas were recognized. This 
panel of T  cells was also investigated with several rabbit anti-human  T  cell antisera 
(7).  Whereas  the antiserum  raised against  fetal thymus  cells contained  only T  cell- 
specific antibodies, the other rabbit sera contained both T cell-specific antibodies and 
antibodies to the antigenic determinants shared by human T  cells and B-CLL cells. 
The same panel of T cell lymphoblasts recognized by A50 was also recognized by one 
rabbit antiserum raised against S~zary cells (Table III). 
Discussion 
The monoclonal antibody A50, obtained after immunization against T-CLL cells, 
recognizes  an  antigen  present  on  the  surface  of T  cells and  B-CLL  cells.  We  had 
previously shown, using rabbit antisera,  that T  cells and B-CLL cells share a set of 
TABLE  III 
Distribution of the Antigen Shared by Human T Cell and B-CLL Cells on T Cell Malignancies 
T  cell malignan-  ASO 
cies 
Rabbit antisera  raised against* 
8dzary  Sdzary  Fetal thy-  Child thy-  T cell 
lyre-  XLA  PBL:~ 
mus  rnus  phoma 
-------T-ALL~  -II  -  -  -  .6  .6  - 
....  4-  +  -- 
....  .6  .6  -- 
....  -4-  +  + 
-  -  -  +ll  +  +  - 
_  _  --  +  +  +  + 
T  cell lymphoma  ....  +  +  - 
....  •  4-  -6  - 
....  -6  -6  - 
....  -6  -6  - 
....  -6  -6  - 
....  -6  -6  - 
....  +  +  + 
....  -6  -6  -6 
--  --  --  4-  -6  -6  .6 
--  --  _  -6  -6  .6  -6 
6  -6  -6  -6  -6  -6  -6 
6  -6  -6  -6  -6  -6  -6 
4-  -6  -  -6  -6  -6  -6 
6  -6  -6  --  -6  -6  -6 
--  --  -6  --  -6  -6  -6 
T-CLL  +  +  -  -  +  +  + 
4-  +  -  _  +  +  -6 
6  -6  -6  -  -6  -6  -6 
Sdzary  +  +  +  --  +  -6  + 
6  +  -6  --  +  -6  + 
6  -6  --  _  -6  -6  -6 
6  -6  --  _  -6  -6  -6 
-6  --  --  --  -6  -6  -6 
-6  --  --  --  -6  --  -6 
* The rabbit antisera are used at a dilution where they recognized  both T cell-specific  antigens and the antigen(s)  shared 
by human T cell and B-CLL cells, 
Same  as Table I. 
§  Results of individual patients with T  cell acute lymphoblastic leukemia (T-ALL)  (6  patients), T  cell  lymphoma  (15") 
patients)  T-CLL (3 patients),  and S~zary disease  (6 patients). 
II A  sample was considered  positive if ;~50% of the cells were lysed  in  a  cell  suspension that  contained 80'7, or more 
malignant cells.  A  sample was considered as negative if 10%  or less of the cells were lysed  in a  cell suspension that 
contained 80% or more malignant cells, BOUMSELL ET AL.  BRIEF  DEFINITIVE REPORT  233 
antigens, and by absorption experiments, we could enumerate at least three different 
determinants within this set (2). The determinant recognized by A50 is not present on 
all  B-CLL cells displaying antigens  belonging to this set, although  it  is present  on 
most of them. It is present on the T-PBL from every normal subject tested, as are the 
determinants defined by rabbit  antisera. The restricted distribution  of these deter- 
minants on B-CLL cells suggests that this set of antigens is more complex than initially 
suspected. Further investigation of the cellular distribution, together with biochemical 
investigations, will permit us to study whether these determinants belong to different 
molecular species or to related molecular structures. 
The fact that we could not find any positive B cells, normal or malignant, other 
than B-CLL cells, does not exclude the possibility that these antigens might be present 
on the surface of a  limited population of normal B cells. Alternatively it should be 
determined why B-CLL cells, contrary to all other malignant B cells, display surface 
antigens normally present on T  cells only. 
The determinant recognized by A50 is not present on all immature T  cells. Surface 
antigens  defined  by  monoclonal  antibodies  and  restricted  to  a  subpopulation  of 
human  T  cells have already been described  (10-12).  These monoclonal antibodies 
provide us with new insights into the stages of intrathymic differentiation and will 
permit a better analysis of malignant T cell proliferations. We have previously defined 
three subsets of malignant T  lymphoblasts that are correlated with other markers of 
T  cell maturation using rabbit anti-human T  cell antisera (9). A similar subclassifi- 
cation of T  cell lymphoblasts has also been observed using monoclonal antibodies 
(10).  The demonstration of the heterogeneity of malignant  lymphoid proliferations 
has many implications including those of direct clinical importance. 
Summary 
We obtained a monoclonal antibody, A50, after immunizing Biozzi's high responder 
strain of mice with T cell chronic lymphocytic leukemia (T-CLL) cells. A50 recognized 
an antigen present on the surface of B cell chronic lymphocytic leukemia cells from 
many patients and from cells of T  lineage from any subject we tested. We could not 
find  this  antigen  either  on  the  surface  of normal  B  cell  or  on  other  non-T  cell 
malignancies.  On  T  cells,  this  antigen  was  present  on a  subpopulation  of thymus 
cells, and on most peripheral T  cells. The antigen was present on the surface of cells 
from T-CLL, S6zary's disease, and a subset of T  cell lymphoma. The antigen seemed 
to belong to a complex set of antigenic determinants that we had defined with rabbit 
antisera. 
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